Cargando…

Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system

It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., 1752). Since then, metastatic spread of cancer cells to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlsson, Mikael C., Gonzalez, Santiago F., Welin, Josefin, Fuxe, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496496/
https://www.ncbi.nlm.nih.gov/pubmed/28590032
http://dx.doi.org/10.1002/1878-0261.12092
_version_ 1783247991645143040
author Karlsson, Mikael C.
Gonzalez, Santiago F.
Welin, Josefin
Fuxe, Jonas
author_facet Karlsson, Mikael C.
Gonzalez, Santiago F.
Welin, Josefin
Fuxe, Jonas
author_sort Karlsson, Mikael C.
collection PubMed
description It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., 1752). Since then, metastatic spread of cancer cells to regional lymph nodes has been established as the most important prognostic factor in many types of cancer (Carter et al., 1989; Elston and Ellis, 1991). However, despite its clinical importance, lymph metastasis remains an underexplored area of tumor biology. Fundamental questions, such as when, how, and perhaps most importantly, why tumor cells disseminate through the lymphatic system, remain largely unanswered. Accordingly, no treatment strategies exist that specifically target lymph metastasis. The identification of epithelial‐mesenchymal transition (EMT) as a mechanism, which allows cancer cells to dedifferentiate and acquire enhanced migratory and invasive properties, has been a game changer in cancer research. Conceptually, EMT provides an explanation for why epithelial cancers with poor differentiation status are generally more aggressive and prone to metastasize than more differentiated cancers. Inflammatory cytokines, such as TGF‐β, which are produced and secreted by tumor‐infiltrating immune cells, are potent inducers of EMT. Thus, reactivation of EMT also links cancer‐related inflammation to invasive and metastatic disease. Recently, we found that breast cancer cells undergoing TGF‐β‐induced EMT acquire properties of immune cells allowing them to disseminate in a targeted fashion through the lymphatic system similar to activated dendritic cells during inflammation. Here, we review our current understanding of the mechanisms by which cancer cells spread through the lymphatic system and the links to inflammation and the immune system. We also emphasize how imaging techniques have the potential to further expand our knowledge of the mechanisms of lymph metastasis, and how lymph nodes serve as an interface between cancer and the immune system.
format Online
Article
Text
id pubmed-5496496
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54964962017-07-18 Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system Karlsson, Mikael C. Gonzalez, Santiago F. Welin, Josefin Fuxe, Jonas Mol Oncol Reviews It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., 1752). Since then, metastatic spread of cancer cells to regional lymph nodes has been established as the most important prognostic factor in many types of cancer (Carter et al., 1989; Elston and Ellis, 1991). However, despite its clinical importance, lymph metastasis remains an underexplored area of tumor biology. Fundamental questions, such as when, how, and perhaps most importantly, why tumor cells disseminate through the lymphatic system, remain largely unanswered. Accordingly, no treatment strategies exist that specifically target lymph metastasis. The identification of epithelial‐mesenchymal transition (EMT) as a mechanism, which allows cancer cells to dedifferentiate and acquire enhanced migratory and invasive properties, has been a game changer in cancer research. Conceptually, EMT provides an explanation for why epithelial cancers with poor differentiation status are generally more aggressive and prone to metastasize than more differentiated cancers. Inflammatory cytokines, such as TGF‐β, which are produced and secreted by tumor‐infiltrating immune cells, are potent inducers of EMT. Thus, reactivation of EMT also links cancer‐related inflammation to invasive and metastatic disease. Recently, we found that breast cancer cells undergoing TGF‐β‐induced EMT acquire properties of immune cells allowing them to disseminate in a targeted fashion through the lymphatic system similar to activated dendritic cells during inflammation. Here, we review our current understanding of the mechanisms by which cancer cells spread through the lymphatic system and the links to inflammation and the immune system. We also emphasize how imaging techniques have the potential to further expand our knowledge of the mechanisms of lymph metastasis, and how lymph nodes serve as an interface between cancer and the immune system. John Wiley and Sons Inc. 2017-06-26 2017-07 /pmc/articles/PMC5496496/ /pubmed/28590032 http://dx.doi.org/10.1002/1878-0261.12092 Text en © 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Karlsson, Mikael C.
Gonzalez, Santiago F.
Welin, Josefin
Fuxe, Jonas
Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
title Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
title_full Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
title_fullStr Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
title_full_unstemmed Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
title_short Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
title_sort epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496496/
https://www.ncbi.nlm.nih.gov/pubmed/28590032
http://dx.doi.org/10.1002/1878-0261.12092
work_keys_str_mv AT karlssonmikaelc epithelialmesenchymaltransitionincancermetastasisthroughthelymphaticsystem
AT gonzalezsantiagof epithelialmesenchymaltransitionincancermetastasisthroughthelymphaticsystem
AT welinjosefin epithelialmesenchymaltransitionincancermetastasisthroughthelymphaticsystem
AT fuxejonas epithelialmesenchymaltransitionincancermetastasisthroughthelymphaticsystem